» Articles » PMID: 35320938

Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate

Overview
Journal Front Immunol
Date 2022 Mar 24
PMID 35320938
Authors
Affiliations
Soon will be listed here.
Abstract

The versatility of natural killer cells has ignited growing interest in their therapeutic use for cancer and other immunotherapy treatments. However, NK cells compose a small portion of peripheral blood mononuclear cells (5%-20% of PBMCs) and clinical doses require billions of cells. Manufacturing suitable doses of NK cells remains a major challenge for NK immunotherapy. The current standard for expanding NK cells relies on feeder cells and fetal bovine serum to achieve large expansion, but both encounter regulatory concerns. We developed NK Cloudz, a dissolvable polymer-based microsphere platform, as an alternative to a feeder cell approach to expand NK cells. We demonstrated that a combination of NK Cloudz, a G-Rex6M culture vessel, and GMP Human Platelet Lysate expanded NK cells 387 ± 100-fold in 10 days from a PBMC starting population. The NK purity, viability, and cytotoxicity were similar to both a feeder cell protocol and an FBS-based protocol. Additionally, we found no significant differences between FBS and GMP Human Platelet Lysate and concluded that platelet lysate is a good xeno-free alternative to FBS for NK expansion. Overall, we demonstrated a feeder-cell-free and FBS-free protocol that leverages NK Cloudz as a promising step toward a commercial GMP manufacturing method to expand NK cells for therapeutic use.

Citing Articles

Human platelet lysate as a substitute for serum in natural killer cell generation and expansion.

Li C, Zhu H, Zhang L, Liu X, Ji Y, Zhang H Life Med. 2025; 2(2):lnad011.

PMID: 39872107 PMC: 11749240. DOI: 10.1093/lifemedi/lnad011.


The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.

Yao P, Liu Y, Huang G, Hao L, Wang R Exp Hematol Oncol. 2024; 13(1):118.

PMID: 39633491 PMC: 11616395. DOI: 10.1186/s40164-024-00583-7.


Comparison of Natural Killer Cells Differentiated from Various Pluripotent Stem Cells.

Han J, Son H, Jung D, Kim K, Jin C, Hwang H Int J Mol Sci. 2024; 25(15).

PMID: 39125777 PMC: 11311719. DOI: 10.3390/ijms25158209.


Scalable process development of NK and CAR-NK expansion in a closed bioreactor.

Wang X, Byrne M, Liu C, Ma M, Liu D Front Immunol. 2024; 15:1412378.

PMID: 39114666 PMC: 11303211. DOI: 10.3389/fimmu.2024.1412378.


Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.

Mohammad Taheri M, Javan F, Poudineh M, Athari S J Transl Med. 2024; 22(1):736.

PMID: 39103889 PMC: 11302387. DOI: 10.1186/s12967-024-05534-8.


References
1.
Miller J . Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program. 2013; 2013:247-53. DOI: 10.1182/asheducation-2013.1.247. View

2.
Witzeneder K, Lindenmair A, Gabriel C, Holler K, Theiss D, Redl H . Human-derived alternatives to fetal bovine serum in cell culture. Transfus Med Hemother. 2014; 40(6):417-23. PMC: 3901599. DOI: 10.1159/000356236. View

3.
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B . Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2014; 38(1):24-36. PMC: 4352951. DOI: 10.1097/CJI.0000000000000059. View

4.
Hildner F, Eder M, Hofer K, Aberl J, Redl H, van Griensven M . Human platelet lysate successfully promotes proliferation and subsequent chondrogenic differentiation of adipose-derived stem cells: a comparison with articular chondrocytes. J Tissue Eng Regen Med. 2013; 9(7):808-18. DOI: 10.1002/term.1649. View

5.
Pomeroy E, Hunzeker J, Kluesner M, Lahr W, Smeester B, Crosby M . A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Mol Ther. 2019; 28(1):52-63. PMC: 6953961. DOI: 10.1016/j.ymthe.2019.10.009. View